The Short Version
Stem cell regulation in the United States has two layers. Federal law from the FDA sets a nationwide floor for how human tissue is handled. On top of that, individual states have passed their own laws about disclosure, informed consent, advertising, and which providers may offer regenerative procedures. These state laws vary widely. Some states, such as Florida and Wyoming, have passed authorization laws that permit certain procedures under specific conditions. Others, such as California and Utah, require clinics to post disclosure notices and give patients written warnings. This page summarizes the major state laws in plain language and shows how they interact with federal rules. It is educational, not legal advice, and laws change often.
Important: This page is a plain-language educational summary of state laws. It is not legal advice, not medical advice, and not a substitute for a qualified attorney. Laws change frequently and effective dates vary, so every detail here should be verified against the current statute and confirmed with counsel before you rely on it. SaveMyFat is a connector that links patients and providers with a U.S.-based tissue bank for adipose tissue banking; it does not collect, process, or store tissue itself, and it does not provide treatments or cures for any disease. Banking does not guarantee future eligibility, access, or benefit.
Why State Law Varies, and Why It Matters
The FDA framework applies in every state, but it is only the floor. Individual states regulate the practice of medicine, professional licensing, advertising, and consumer protection, and several have used that authority to pass laws aimed specifically at stem cell and regenerative procedures. The result is a patchwork: the same product can be handled very differently depending on where a clinic operates.
Broadly, these laws fall into a few groups. Authorization laws set conditions under which licensed physicians may offer certain procedures. Disclosure laws require clinics to warn patients, in writing, that a treatment is not FDA-approved. This page walks through the major examples, then pulls them together in a comparison table you can scan. For the underlying overview, see our multi-state stem cell law map.
It is worth saying what is not on this list. Most states have no stem cell specific statute at all. In those states, regenerative procedures are governed by the federal FDA framework, general medical-practice and licensing rules, and ordinary consumer-protection law, without a dedicated posting or authorization regime. The absence of a state law does not mean anything is permitted. It means the federal floor and the general rules are what apply. Because legislatures act every session, a state with no law today may pass one next year, which is why this page reflects the landscape as of July 2026 and is reviewed quarterly.
Authorization States: Florida and Wyoming
Florida passed SB 1768 (Chapter 2025-185), which took effect on July 1, 2025 and is codified at Florida Statutes sections 458.3245 and 459.0127. It authorizes licensed MDs and DOs to offer certain regenerative treatments, with a focus on orthopedic, wound care, and pain applications, provided they obtain signed informed consent and include an advertising notice sized to the largest type used in the advertisement. Penalties run through medical-board discipline, and the law includes a separate felony provision tied to abortion-derived material. We break down the details in the Florida SB 1768 physician checklist and what SB 1768 means for advertising.
Wyoming enacted the Stem Cell Freedom Act (SF 48), codified at W.S. 35-4-1101 and following, effective July 1, 2026. It allows MDs and DOs who register with the board to offer autologous mesenchymal stem cell procedures with signed consent. Unlike a disclosure law, it is not a posting regime; instead, providers who comply are shielded from board action. See our guide to the Wyoming Stem Cell Freedom Act and the related note on IRB approval versus investigational status under SF 48. Important context: a state authorization law permits a procedure under state licensing rules, but it does not change the product’s federal classification. A 351 biologic still needs FDA approval or an active IND.
Disclosure-Only States: California and Utah
California was an early mover with SB 512, codified at Business and Professions Code section 684, effective in 2018. It does not authorize new procedures. Instead, it requires health care providers who offer treatments involving non-FDA-approved stem cell products to post a notice, on an 8.5 by 11 inch sign in 40-point type, at the entrance and in the treatment area, and to give patients a written handout. Penalties reach up to $1,000 per violation, generally not applied on a first complaint. See our overview of the California stem cell disclosure law.
Utah takes a disclosure approach with added supply-chain obligations, codified at Utah Code 58-1-512, first passed as SB 199 in 2024 and amended by SB 275 in 2025. It requires a posted notice, again on an 8.5 by 11 inch, 40-point sign, along with signed consent, and under the 2025 amendment it adds notice obligations for suppliers. Violations are treated as unprofessional conduct under the state’s professional-licensing authority. Our Utah disclosure law guide covers the supplier and provider duties in detail.
Master Comparison Table
The table below summarizes the major state laws in one place. It is built to be updated as legislation changes, which is the whole point of a living reference. Every entry is a plain-language summary for education, not a legal citation you should rely on without checking the current statute.
Summary for education only. Verify every entry against the current statute and with qualified counsel. Reviewed quarterly; last reviewed July 2026.
The Federal Floor That Applies Regardless of State Law
No matter what a state law says, the federal framework still applies. The FDA regulates human cells and tissues under 21 CFR Part 1271, and the 361 versus 351 distinction decides whether a product needs clinical trials and approval before it can be marketed to treat disease. A state authorization law can permit a licensed physician to offer a procedure under state rules, but it cannot turn an unapproved 351 biologic into an approved one. If the product would need an IND or a BLA federally, it still needs one, even in an authorization state.
This is why the two layers have to be read together. For the federal side of the picture, see our FDA regulation of adipose tissue and stem cells hub, and the FDA’s own consumer alert on regenerative medicine products. Adipose tissue banking itself is a preservation service under the federal tissue rules, distinct from any treatment a state law might address.
State authorization also does not shield a clinic from federal enforcement. The FDA and the Federal Trade Commission can still act against products marketed with unproven disease claims, regardless of a permissive state law, so real compliance means satisfying both layers at once rather than treating a state statute as a green light.
What This Means for Patients and Providers
For patients, the practical lesson is to be careful with marketing that leans on a state law. A clinic in an authorization state may say a procedure is legal in this state, which can be true under state licensing rules while the product itself remains unapproved by the FDA. Before agreeing to anything, ask which specific product is being used, whether it is FDA-approved or part of a registered clinical trial, and what the written disclosure actually says. Legality under state law is not the same as proof that a treatment is safe or effective.
For providers, these laws are compliance obligations, not marketing advantages. Meeting a state’s consent and disclosure requirements does not resolve a product’s federal classification, and it does not protect against advertising enforcement if claims outrun the evidence. Physicians offering or weighing regenerative procedures should read the current statute in their own state, document informed consent carefully, and keep advertising claims within what the science supports. Where banking is involved, remember that preservation and treatment are separate steps governed by different rules.